Department of Cardiology, Thoraxcentrum, Twente, the Netherlands, and Medisch Spectrum Twente, Enschede, the Netherlands.
Am J Cardiol. 2012 Dec 1;110(11):1561-7. doi: 10.1016/j.amjcard.2012.07.019. Epub 2012 Aug 31.
In patients without a history of diabetes mellitus, increased levels of glycated hemoglobin (HbA1c) are associated with higher cardiovascular risk. The relation between undetected diabetes and clinical outcome after percutaneous coronary intervention is unknown. To investigate whether these patients may have an increased risk of periprocedural myocardial infarction (PMI), the most frequent adverse event after percutaneous coronary intervention, we assessed patients of the TWENTE trial (a randomized, controlled, second-generation drug-eluting stent trial) in whom HbA1c data were available. Patients were classified as known diabetics or patients without a history of diabetes who were subdivided into undetected diabetics (HbA1c ≥6.5%) and nondiabetics (HbA1c <6.5%). Systematic measurement of cardiac biomarkers and electrocardiographic assessment were performed. One-year clinical outcome was also compared. Of 626 patients, 44 (7%) were undetected diabetics, 181 (29%) were known diabetics, and 401 (64%) were nondiabetics. In undetected diabetics the PMI rate was higher than in nondiabetics (13.6% vs 3.7%, p = 0.01) and known diabetics (13.6% vs 6.1%, p = 0.11). Multivariate analysis adjusting for covariates confirmed a significantly higher PMI risk in undetected diabetics compared to nondiabetics (odds ratio 6.13, 95% confidence interval 2.07 to 18.13, p = 0.001) and known diabetics (odds ratio 3.73, 95% confidence interval 1.17 to 11.89, p = 0.03). After 1 year, target vessel MI rate was significantly higher in undetected diabetics (p = 0.02) than in nondiabetics, which was related mainly to differences in PMI. Target vessel failure was numerically larger in unknown diabetics than in nondiabetics, but this difference did not reach statistical significance (13.6% vs 8.0%, p = 0.25). In conclusion, undetected diabetics were shown to have an increased risk of PMI.
在没有糖尿病病史的患者中,糖化血红蛋白(HbA1c)水平升高与心血管风险增加相关。未检测到的糖尿病与经皮冠状动脉介入治疗后的临床结局之间的关系尚不清楚。为了研究这些患者在经皮冠状动脉介入治疗后最常见的不良事件——围手术期心肌梗死(PMI)的风险是否增加,我们评估了 TWENTE 试验(一项随机、对照、第二代药物洗脱支架试验)中可获得 HbA1c 数据的患者。将患者分为已知糖尿病患者或无糖尿病病史的患者,并进一步分为未检出的糖尿病患者(HbA1c≥6.5%)和非糖尿病患者(HbA1c<6.5%)。系统地测量了心脏生物标志物和心电图评估。并比较了 1 年的临床结局。在 626 例患者中,44 例(7%)为未检出的糖尿病患者,181 例(29%)为已知的糖尿病患者,401 例(64%)为非糖尿病患者。在未检出的糖尿病患者中,PMI 发生率高于非糖尿病患者(13.6%比 3.7%,p=0.01)和已知的糖尿病患者(13.6%比 6.1%,p=0.11)。多变量分析调整了混杂因素后,证实与非糖尿病患者相比,未检出的糖尿病患者的 PMI 风险显著增加(比值比 6.13,95%置信区间 2.07 至 18.13,p=0.001),与已知的糖尿病患者相比,未检出的糖尿病患者的 PMI 风险也显著增加(比值比 3.73,95%置信区间 1.17 至 11.89,p=0.03)。1 年后,未检出的糖尿病患者的靶血管心肌梗死发生率明显高于非糖尿病患者(p=0.02),这主要与 PMI 的差异有关。未知的糖尿病患者的靶血管失败率大于非糖尿病患者,但差异无统计学意义(13.6%比 8.0%,p=0.25)。总之,未检出的糖尿病患者发生 PMI 的风险增加。